AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02058459 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Holaira™ Lung Denervation System without energy delivery
Study NCT01700907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
Study NCT01700907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
Study NCT01097759 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
Study NCT03612830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy endoscopy cooperated surgery
Description: LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
Study NCT03612830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dan Vinchi robot endoscopy cooperated surgery
Description: RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
Study NCT01708252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT00213629 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: transcriptome analysis
Description: transcriptome analysis from muscle biopsy
Study NCT00213629 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: T cell repertoire analysis
Description: blood T cell repertoire analysis
Study NCT01055184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2009 H1N1 Virus Vaccine
Description: Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
Study NCT00860054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Different amount of phytosterols are added into diets
Description: Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
Study NCT00860054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Different amount of phytosterols are added into diets
Description: Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
Study NCT01419405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: hard capsule, 150 mg, 2 times, 2 days
Study NCT01419405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
Study NCT02664662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tailored education
Description: Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
Study NCT00517881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
Description: Subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 mcg every 4 weeks for 20 weeks. Further dose adjustments will be performed during the study depending on the participant's blood hemoglobin levels.
Study NCT00800267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005%
Description: placebo in the morning and latanoprost .005% in the evening
Study NCT00800267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed combination latanoprost-timolol
Description: one drop in the morning and placebo in the evening
Study NCT00800267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: timolol 0.5%
Description: one drop in the morning and evening
Study NCT01950455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAV5001
Description: A single intravenous dose of 8.0 ± 1.0 mCi
Study NCT04389229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600mg/m2/day for 3 days ( on day -5, -4, -3)
Study NCT04389229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: 30mg/m2/day for 3 days ( on day -5, -4, -3)
Study NCT04389229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 (Proleukin)
Description: Subcutaneous injections at a fixed dose of 18 million units once a day following TIL infusion
Study NCT04389229 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Unmodified Tumour Infiltrating Lymphocytes (UTIL-01)
Description: Single dose at 5 x 10\^9 - 5 x 10\^10
Study NCT04389229 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene modified Tumour Infiltrating Lymphocytes (CoTIL-01)
Description: Single dose at 2 x10\^9 (+/- 20%) (engineered TIL)
Study NCT00449904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: Administered orally
Study NCT04271228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Advisor Pro
Description: Using the DreaMed Advisor Pro as an advisory tool for Health Care Professionals during routine clinical use
Study NCT01001650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)
Description: Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If > 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose.
Study NCT05748743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glove changing
Description: Surgical gloves were changed prior to abdominal closure during Cesarean section to evaluate its effectiveness in reducing wound complications after surgery
Study NCT02038010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BYL719
Description: Given PO
Study NCT02038010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Description: Given IV
Study NCT02038010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02038010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT03569410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: increased protein intake via natural foods
Description: Patients had to eat 1.4g/kg/day of natural protein.
Study NCT03569410 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: increase protein intake via protein supplements
Description: Patients ate enough protein supplements in addition to their regular diet to reach eat 1.4g/kg/day of protein intake.
Study NCT04507399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liquid Model
Description: To study the perception of whey beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying)~Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein and whey permeate beverages.
Study NCT01750801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propolis
Description: Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
Study NCT01750801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
Study NCT03182231 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: 68Ga-NODAGA-exendin-4 PET/CT
Study NCT01307332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MabCampath-1h
Description: Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.
Study NCT02445716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.~Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.~Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit.
Study NCT02445716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
Study NCT04403724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl-Morphine.
Description: 2.4 ml Bupivacaine 0.5%, 20 µg Fentanyl and, 100 µg preservative free morphine
Study NCT00962819 — intervention group
Intervention type: BIOLOGICAL
Intervention: MMR vaccine
Description: People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
Study NCT02933164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System
Description: Effectiveness and safety of a Continuous Glucose Monitoring System
Study NCT03995641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: marcaine and kenalog
Description: Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
Study NCT00718874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary
Description: modification of macronutrient content
Study NCT01787292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Exercise Intervention
Description: A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
Study NCT01787292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Intervention
Description: Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.
Study NCT01787292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Monitoring
Description: 6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
Study NCT04196283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-368
Description: Intravenous (IV) infusion
Study NCT04196283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: Intratumoral (IT) injection
Study NCT00025883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Drug treatment
Study NCT04413929 — intervention group
Intervention type: DRUG
Intervention: Ergoferon
Description: Oral administration
Study NCT03806582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: intervention with norepinephrine to reach a MAP of 85 mmHg
Study NCT01419405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
Study NCT01419405 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill, saline infusion
Description: hard capsule, 150 mg, 2 times, 2 days, saline infusion
Study NCT04129866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-IBM
Description: In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect.
Study NCT04129866 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control-IBM
Description: Placebo IBM where sentences are not related to anxious threat meaning of cue word.
Study NCT03710759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assistive autogenic Drainage
Description: Assistive autogenic Drainage : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
Study NCT02423057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TdCyd
Description: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. TdCyd offers an improvement over current DNMT inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
Study NCT02919761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: 80 Units Acthar Gel per 1 mL for subcutaneous injection
Study NCT02919761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 1 mL for subcutaneous injection
Study NCT02551341 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: higher PEEP ventilation
Study NCT03072173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Description: Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
Study NCT02987114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLT101
Description: PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
Study NCT03072173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (saline)
Description: Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
Study NCT03372265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Description: Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
Study NCT03372265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
Study NCT01254799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: 100 mg Doxycycline capsules twice daily for 5 days
Study NCT01254799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice daily for 5 days
Study NCT02983773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 7.2%
Description: 1 smoked marijuana cigarette with 7.2% THC
Study NCT02983773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 3.0%
Description: 1 smoked marijuana cigarette with 3.0% THC
Study NCT02983773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 smoked placebo marijuana cigarette
Study NCT01002118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Acid Ethyl Esters
Description: 1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
Study NCT01002118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules each day for 16 weeks
Study NCT05859893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical Turkish Music Sessions
Description: The participants attended an interactive livestreamed music performance. In selecting the mode, tempo, and songs to be performed, recommendations were obtained from the Applied Music Therapies Association, and the pieces with copyrighted recordings presented by the Edirne State Turkish Music Ensemble, under the leadership of the General Directorate of Fine Arts of the Ministry of Culture and Tourism. As part of the project, examples of traditional Turkish songs were presented to the elderly. The recommended genres and songs consist of vocal and instrumental works belonging to major and minor scales from the Classical Period, which spans from the 14th to the 20th century. In this respect an assembly of eight-musican consisting of five artists playing kanun, tanbur, ney, classical kemençe, and bendir, as well as two vocal soloists performed.
Study NCT00901420 — intervention group
Intervention type: PROCEDURE
Intervention: Urodynamics Test
Description: 90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
Study NCT01650194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
Study NCT00901420 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
Study NCT01650194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
Study NCT01650194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
Study NCT00452790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 1 dose at 6, 10, 14 weeks and 12 months of age
Study NCT00452790 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7 valent pneumococcal conjugate vaccine
Description: 1 dose at 6, 10, 14 weeks and 12 months of age
Study NCT01308697 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative fixation of flail chest
Description: Plate fixation
Study NCT01308697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Operative management
Description: Non Operative treatment of Flail Chest
Study NCT03621657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose FMT Capsule DE
Description: 5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.
Study NCT03621657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single Dose FMT Capsule DE
Description: 30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.